Top Markets
Coin of the day
Gamida Cell Ltd. Gamida Cell Ltd.

Gamida Cell Ltd.

GMDA
Rang in aandelen #35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Aandeelprijs
$0.0327
Laatst gesynchroniseerd: 2025-06-17
Marktkapitalisatie
$4.34M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
IL
Handel Gamida Cell Ltd. (GMDA)

Categorie

Koersgeschiedenis voor Gamida Cell Ltd. (GMDA)
Hoogste slotkoers: $0.03 op 2025-06-01

Laagste slotkoers: $9.40 op 2018-10-01
Koersgeschiedenis van Gamida Cell Ltd. van 2018 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2025 117.76%
2024 -95.28%
2023 -75.22%
2022 -48.32%
2021 -71.87%
2020 84.95%
2019 -55.53%
2018 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE